The acquisition includes iLab Solutions’ technology, intellectual property, product portfolio and employee talent.
Mark Doak, president of Agilent CrossLab Group, said the deal boosts its portfolio in a space it previously did not have a presence in.
"iLab's solutions are robust and scalable, allowing for expansion into large-enterprise accounts, including Pharma. With iLab's experience and outstanding enterprise-level management solutions, we will be able to immediately deliver broader value for our customers."
iLab Solutions provides laboratory management services to universities, research hospitals and independent institutes worldwide. It employs nearly 70 people, all of whom will be offered opportunities with Agilent.
Functionality includes request management, equipment reservation and usage tracking, project tracking, billing and invoicing and reporting.
The acquisition is expected to be completed in early August, subject to local laws and regulations and customary closing conditions.
Tad Fallows, CEO of iLab Solutions, said customers will benefit from the integration.
“Together, we'll be able to further accelerate our offerings to additional markets through Agilent's global reach and leadership in multiple market segments."
Qiagen buys Exiqon
Meanwhile, Qiagen has completed its tender offer of DKK 683m (€100m) for Exiqon after amending the bid and timeline three times.
Qiagen has received acceptances from shareholders representing 94.52% of the share capital and voting rights. Following completion of the offer, Qiagen will apply for a delisting of the shares of Exiqon and initiate a squeeze-out of the remaining minority shareholders.
Peer M. Schatz, CEO of Qiagen, said it was pleased to have finally completed the transaction and will now start the integration process.
"We welcome our new employees to the Qiagen family and look forward to further growing the combined RNA technology offering to provide greater benefits to research and diagnostic laboratories.”
Qiagen provides sample technologies to isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis.
It works with more than 500,000 customers in molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing and food safety), pharma (pharma and biotech companies) and academia (life sciences research).